Home > News > NIH Funds Clinical Development of VivaGel(TM)
April 19th, 2006
NIH Funds Clinical Development of VivaGel(TM)
Abstract:
Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL) today signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund a clinical trial to test the use of VivaGel(TM) in the prevention of genital herpes. Genital herpes is the second indication for which VivaGel(TM) is being developed. This latest support from the NIH is in addition to a previously announced US$20.3 (A$26m) million funding provided by the NIH to support the development of VivaGel(TM) for the prevention of HIV.
Source:
prnewswire
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||